medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2022, Number 1

<< Back Next >>

Rev Mex Patol Clin Med Lab 2022; 69 (1)

Levels of IgG antibodies against spike protein of the SARS-CoV-2 virus by chemiluminescence in vaccinated patients

Munive-Lima MR, Akle-Fierro D, Mendoza-Franco HM, Akle-Cantú D

Language: Spanish
References: 8
Page: 6-10
PDF size: 251.82 Kb.


ABSTRACT

Introduction: one way to determine the response to the SARS-Cov-2 vaccine can be done by quantifying IgG antibodies against the Spike protein of the virus (IgGS). Objectives: the objective of the study was to determine if the level of antibodies generated changed with the type of vaccine administered. Material and methods: a descriptive, cross-sectional and prospective study was carried out, with the patients who attended the laboratory, during the period from August 1, 2021 to December 31, 2021, to whom the IgGS study was requested by chemiluminescence, as part of their requested studies, in addition to having their complete vaccination schedule at the time of the study. Results: the results show that in our population the application of vaccines with mRNA platforms predominated. The percentage of positive results obtained in general was 93.7%, the highest proportion of positives was found with Moderna 99.4% (n = 165), Sputnik 96.6% (n = 28) and Pfizer 94.9% vaccines. Conclusions: the titers found cannot be correlated with the efficacy of the vaccine, since it is necessary to analyze other types of variables that can interfere with it.


REFERENCES

  1. Roltgen K, Boyd SD. Antibody and B cell responses to SARS-CoV-2 infection and vaccination. Cell Host Microbe. 2021; 29 (7): 1063-1075.

  2. Bonelli F, Sarasini A, Zierold C, Calleri M, Bonetti A, Vismara C et al. Clinical and analytical performance of an automated serological test that identifies S1/S2-neutralizing IgG in COVID-19 patients semiquantitatively. J Clin Microbiol. 2020; 58 (9): e01224-01220.

  3. Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell. 2020; 183 (4): 1024-1042.e21.

  4. Chiereghin A, Zagari RM, Galli S, Moroni A, Gabrielli L, Venturoli S et al. Recent Advances in the Evaluation of Serological Assays for the Diagnosis of SARS-CoV-2 Infection and COVID-19. Front Public Health. 2021; 8: 620222.

  5. Mishra SK, Pradhan SK, Pati S, Panda BK, Bhattacharya D, Sahu SK et al. Anti-SARS-CoV-2 antibodies among vaccinated healthcare workers: repeated cross-sectional study. J Family Med Prim Care. 2022; 11 (5): 1883-1889.

  6. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E et al. Coronavirus pandemic (COVID-19). (2020). Available in: Data. https://ourworldindata.org/covid-vaccinations?country=OWID_WRL

  7. Acosta-Coley I, Cervantes-Ceballos L, Tejeda-Benítez L, Sierra-Márquez L, Cabarcas-Montalvo M, García-Espiñeira M et al. Vaccines platforms and COVID-19: what you need to know. Tropical Diseases, Travel Medicine and Vaccines. 2022; 8 (1): 1-19.

  8. Li YD, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC. Coronavirus vaccine development: from SARS and MERS to COVID-19. J Biomed Sci. 2020; 27 (1): 1-23.




2020     |     www.medigraphic.com